Physician profile
Michael Innerfield
NPI 1366528739
$7,150.93
in general payments reported to CMS, 2019-2025
23 companies · $604 in 2025
The $604 reported for 2025 was less than what a typical Interventional Cardiology provider received nationally (typical 2025 total: $1,092).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,090 · 2020: $915 · 2021: $754 · 2022: $1,472 · 2023: $1,331 · 2024: $985 · 2025: $604.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,920.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,919.88 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Edwards Lifesciences Corporation | $1,524.54 | 2019-2024 | Sapien 3 Ultra Resilia |
| Abbott Laboratories | $1,301.08 | 2019-2025 | Optis, Mitraclip, Supera |
| Medtronic, INC. | $702.73 | 2022-2024 | Corevalve Evolut R, Micra |
| Shockwave Medical, INC | $683.19 | 2021-2025 | Shockwave Ivl System With The Shockwave C2 Coronary Ivl Catheter, Shockwave Ivl System With The Shockwave C2 Coronary Ivl Catheter |
| Abiomed | $504.45 | 2019-2025 | Impella |
| Boston Scientific Corporation | $478.23 | 2019-2023 | Watchman Flx |
| Terumo Medical Corporation | $396.17 | 2022-2025 | Metacross Otw, Angio-Seal, Glidesheath Slender |
| Cardiovascular Systems INC. | $205.58 | 2019 | |
| Amgen INC. | $174.37 | 2019-2025 | Repatha, Repatha |
| Medtronic Vascular, INC. | $162.62 | 2019 | |
| W. L. Gore & Associates, INC. | $149.87 | 2022 | |
| Endologix LLC | $130.44 | 2019 | |
| Penumbra, INC. | $115.90 | 2022 | |
| Astrazeneca Pharmaceuticals LP | $113.34 | 2019-2025 | Farxiga, Wainua |
| Biosense Webster, INC. | $104.67 | 2022 |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Cordis US Corp. | $98.08 | 2025 | Mynx Control Venous |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $85.36 | 2019-2022 | |
| Arrow International, INC. | $52.64 | 2019 | |
| Pfizer INC. | $51.10 | 2021-2022 | |
| Janssen Pharmaceuticals, INC | $41.20 | 2022 | |
| Novartis Pharmaceuticals Corporation | $34.62 | 2024 | |
| Biomerieux INC | $21.53 | 2019 | |
| Lantheus Medical Imaging, INC. | $19.22 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Innerfield listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.